Pharmacokinetics of a cytochrome P450 2E1 probe, chlorzoxazone, and its 6-hydroxy metabolite in poloxamer 407-induced hyperlipidemic rats

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 4, 2013, Pages 648-656

  Hye Kwon, Mi ^a   Jung Lee, Cheol ^a   Yeon Cho, Yong ^a   Kang, Hee Eun ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYCHLORZOXAZONE; CHLORZOXAZONE; CYTOCHROME P450 2E1; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERLIPIDEMIA; IN VITRO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; RAT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BLOOD PROTEINS; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; HYPERLIPIDEMIAS; LIVER; MALE; MICROSOMES, LIVER; POLOXAMER; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84887360970     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3dw3s     Document Type: Article

References (32)

1. Raasch, R.H., Hyperlipidemias, in Young LY: Koda-Kimble MA (eds), Applied Therapeutics. The Clinical Use of Drugs, Edwards Brothers, Ann Arbor, MI, pp 1743-1760, 1988.
2. Eliot LA, Jamali F. Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. J Pharmacol Exp Ther, 1999; 291:188-193.
3. Eliot LA, Foster RT, Jamali F. Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm Res, 1999; 16:309-313.
4. Shayeganpour A, Korashy H, Patel JP, El-Kadi AO, Brocks DR. The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. Int J Pharm, 2008; 361:78-86.
5. Shayeganpour A, Jun AS, Brocks DR. Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos, 2005; 26:249-257.
6. Sugioka N, Haraya K, Maeda Y, Fukushima K, Takada K. Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats. Biol Pharm Bull, 2009; 32:269-275.
7. Kobuchi S, Fukushima K, Shibata M, Ito Y, Sugioka N, Takada K. Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats. J Pharm Pharmacol, 2011; 63:515-523.
8. Lee JH, Oh JH, Lee YJ. Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats. Xenobiotica, 2011; 41:797-804.
9. Brocks DR, Hamdy DA, Ben-Eltriki M, Patel JP, El-Kadi AO. Effect of rat serum lipoproteins on mRNA levels and amiodarone metabolism by cultured primary rat hepatocytes. J Pharm Sci, 2013; 102:262-270.
10. Lee YS, Kim YW, Kim SG, Lee I, Lee MG, Kang HE. Effects of poloxamer 407-induced hyperlipidemia on the pharmacokinetics of carbamazepine and its 10,11-epoxide metabolite in rats: Impact of decreased expression of both CYP3A1/2 and microsomal epoxide hydrolase. Eur Neuropsychopharmacol, 2012; 22:431-440.
11. Lee YS, Yoon JN, Yoon IS, Lee MG, Kang HE. Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407. Xenobiotica, 2012; 42:766-774.
12. Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int, 2007; 27:764-771.
13. Mehvar R, Vuppugalla R. Hepatic disposition of the cytochrome P450 2E1 marker chlorzoxazone and its hydroxylated metabolite in isolated perfused rat livers. J Pharm Sci, 2006; 95:1414-1424.
14. Jung HY, Kang HE, Choi YH, Kim SH, Lee MG. Time-dependent effects of Klebsiella pneumoniae endotoxin on the pharmacokinetics of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, in rats: restoration of the parameters in 96 hour in KPLPS rats to control levels. Biopharm Drug Dispos, 2009; 30:485-493.
15. Lee JH, Lee MG. Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res, 2008; 25:1915-1924.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976; 72:248-254.
17. Duggleby RG. Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol, 1995; 249:61-90.
18. Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci, 1984; 73:774-780.
19. Øie S, Guentert TW. Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer. J Pharm Sci, 1982; 71:127-128.
20. Ahn CY, Bae SK, Jung YS, Lee I, Kim YC, Lee MG, Shin WG. Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus. Drug Metab Dispos, 2008; 36:1233-1241.
21. Wong A, Bandiera SM. Induction of hepatic cytochrome P450 2B and P450 3A isozymes in rats by zolazepam, a constituent of Telazol. Biochem Pharmacol, 1998; 55:201-207.
22. Plate AY, Crankshaw DL, Gallaher DD. The effect of anesthesia by diethyl ether or isoflurane on activity of cytochrome P450 2E1 and P450 reductases in rat liver. Anesth Analg, 2005; 101:1063-1064.
23. Moon YJ, Lee AK, Chung HC, Kim EJ, Kim SH, Lee DC, Lee I, Kim SG, Lee MG. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos, 2003; 31:776-784.
24. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm, 1978; 6:539-546.
25. Gibaldi, M., Perrier, D., Pharmacokinetics, 2nd ed. Marcel-Dekker, New York, NY, 1982.
26. Johnston TP, Palmer WK. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol, 1993; 46:1037-1042.
27. Leon C, Wasan KM, Sachs-Barrable K, Johnston TP. Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating lowdensity lipoprotein receptor expression. Pharm Res, 2006; 23:1597-1607.
28. Palmer WK, Emeson EE, Johnston TP. The poloxamer 407-induced hyperlipidemic atherogenic animal model. Med Sci Sports Exerc, 1997; 29:1416-1421.
29. Kaneko I, Fukumori Y, Fukuda T, Takeuchi Y. Disposition of chlorzoxazone dissolved in polyethylene glycol in rats. Yakuzaigaku, 1990; 50: 166-171.
30. Gao N, Zou D, Qiao HL, Concentration-dependent inhibitory effect of Baicalin on the plasma protein binding and metabolism of chlorzoxazone, a CYP2E1 probe substrate, in rats in vitro and in vivo. PLoS One, 2013; 8:e53038.
31. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res, 1993; 10:1093-1095.
32. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther, 1975; 18:377-390.